ZYBERNO
Stock Report
Updated Sep 1, 2026

VISTAGEN THERAPEUTICS, INC. (VTGN)

Healthcare • NASDAQ

$0.26

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
28.0/100
POOR BUSINESS
VISTAGEN THERAPEUTICS, INC. (VTGN) scores 28/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-152.6%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.13x)
Operating Margin (Operational Efficiency):CRITICAL (-5,490.1%)
Return on Capital (Capital Efficiency):CRITICAL (-631.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

VISTAGEN THERAPEUTICS, INC. (VTGN) stock report — Zyberno Score 28/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.26
Market Cap:$10.96M

Valuation Multiples (3)

P/B Ratio:0.45x
P/S Ratio:8.64x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$5.25M

Price Action & Momentum (1)

% of 52-Week High:5.0%
B. Profitability Assessment

Return Metrics (5)

ROA:-117.5%
Reinvestment Rate:0.4%
Fundamental Growth Rate (g):-2.4%

Margin Analysis (3)

Operating Margin Ttm:-5,490.1%
Net Margin Ttm:-5,328.6%
Ebitda Margin:-5,473.5%

TTM Performance (2)

Operating Margin Ttm:-5,490.1%
Net Margin Ttm:-5,328.6%

Yield Metrics (2)

Earnings Yield:-$620.33
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:33.1%
Latest Earnings Filed:2026-08-14

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):3.4%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:3.07x
Quick Ratio:3.07x
Cash Ratio:1.52x

Leverage Analysis (3)

Debt To Equity Ttm:0.13x
Debt-to-Equity Ratio:0.13x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:23,118,000.00
Cash And Cash Equivalents:16,991,000.00
Long Term Debt:$63.00K
Net Debt:-$16.21M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $1.27M
Linear Growth: 3.4%
📊 Click to view full VTGN Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$69.67M

Bottom Line Performance (3)

-$67.62M
Income Before Tax:-$67.61M
Ebitda Ttm:-69,459,000.00

Operating Expenses (5)

Operating Expenses:72,171,000.00
R And D Expense:54,202,000.00
Sga Expense:17,969,000.00
Income Tax Expense:$7.00K
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:11,681.5%
Sga To Revenue Percentage:3,872.6%
Ebitda Margin:-5,473.5%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$35.74M
Current Assets:$34.31M
Ppe Net:375,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:11,255,000.00
Current Liabilities:11,192,000.00
Long Term Debt:$63.00K
Short Term Debt:$720.00K

Equity & Capital (3)

Equity:$24.48M
Retained Earnings:-$490.35M
Common Stock:325,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:9,238,000.00

Special Items (2)

Contract Liabilities:234,000.00
Stock Based Compensation:991,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$62.30M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$909.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:928,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:211,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.66
-$1.66
Earnings Per Share Ttm:-$1.57

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.03
Operating Cash Flow Per Share:-$1.55

Book Value & Capital (2)

Book Value Per Share:$0.57
Cash Per Share:0.40

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.02x
Working Capital Turnover Ttm:0.05x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:2,657.11
Cash Conversion Cycle:-4,655.11
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.4%
Fundamental Growth Rate (g):-2.4%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):3.4%

Other Growth Rates (1)

Book Value Growth Rate (Linear):5.2%
C. Company Profile & Context

Corporate Information (6)

Symbol:VTGN
Company Name:VISTAGEN THERAPEUTICS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:42.98M
Shares Outstanding Basic:42.98M
Shares Outstanding Diluted:42.98M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 11:34:52 UTC
Data Timestamp:2026-08-21T03:51:24.297317
Scroll to Top